Skip to content
DraconiticResearch
Search Sources API
186,631 studies31 sourcesUpdated just now
Peer-reviewedCC BY-NCJournal of Nutrition

Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial

Abstract

BACKGROUND: Omega-3 (n-3) fatty acid (FA) supplements increase blood concentrations of EPA and DHA. Most of the supplements on the market are esterified in triglycerides (TGs) or ethyl esters (EEs), which limits their absorption and may cause gastrointestinal side effects. OBJECTIVE: The objective of this study was to compare the 24-h AUC of the plasma concentrations of EPA, DHA, and EPA+DHA when provided esterified in monoglycerides (MAGs), EEs, or TGs, (primary outcomes) and evaluate their side effects over 24 h (secondary outcome). METHODS: This was a randomized, triple-blind, crossover, controlled clinical trial. Eleven women and 11 men between 18 and 50 y of age ingested, in random order, a single oral dose of ∼1.2 g of EPA and DHA esterified in MAGs, EEs, and TGs with low-fat meals provided during the 24-h follow-up. Eleven blood samples over 24 h were collected from each participant, and the plasma n-3 FAs were quantified. Friedman's paired ANOVA statistical rank test was used for the pharmacokinetic parameters and a chi-square statistical test was used for the side effects. RESULTS: The 24-h AUC of plasma EPA was ∼2 times and ∼1 time higher after the MAG compared with the EE and TG forms of n-3 FAs, respectively (P ≤ 0.0027). Effects of the EE and TG treatments did not differ. The 3 supplements had similar eructation, dysgeusia, abdominal discomfort, nausea, and bloating side effects. CONCLUSIONS: The plasma n-3 FA concentration in adults is greater after acute supplementation with n-3 FAs esterified in MAGs rather than in EEs or TGs, suggesting that with a lower dose of MAG n-3 FAs, the plasma n-3 FA concentrations attained are similar to those after higher doses of n-3 FAs esterified in EEs or TGs. This trial is registered at www.clinicaltrials.gov as NCT03897660.

Related

  1. Safety, pharmacokinetics and pharmacodynamics of ICP-332, an oral TYK2 inhibitor, in healthy participants: a randomized, double-blind, placebo-controlled phase I study
    Hengli Zhao, Yilin Wei, Yu jiang +4
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textImmunologyCrossrefEurope PMCPMC
  2. Metabolic biomarkers and milk production indicators associated with elevated non-esterified fatty acids in holstein dairy cows
    Samanta Grigė, Akvilė Girdauskaitė, Inga Sabeckienė +5
    BMC Veterinary ResearchPeer-reviewedCC BY-NC-ND 4.0Full textPlant biologyPMC
  3. Pollen as a supplemental or alternative nutritional resource for Typhlodromus transvaalensis Nesbitt (Acari: Phytoseiidae), a predatory mite targeting physic nut pests
    Silvia Lorena Montero-Cedeño, Ernesto Gonzalo Cañarte-Bermúdez, Renato Almeida Sarmento
    AcarologiaPeer-reviewedCC BY 4.0Full textZoology & animal behaviourHAL
  4. Supplemental water modulates pollinator visitation on resource-rich plant species
    J. E. Cohen, S. Austin, A. M. Sauceda +5
    bioRxivPreprintCC BYFull textEcologybioRxiv
  5. Characterization of the Aromatic Profile of Mature-Green Tomato Fruit (‘Fen Junmei’) in Response to Supplemental LED Light Quality and Intensity During Ripening
    Jingli Yang, Xiaohan Yu, Qingyu Wang +6
    International Journal of Molecular SciencesPeer-reviewedCC BY 4.0Plant biologyCrossref
BibTeX
@article{chevalier2026pharmacokinetics,
  title = {{Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial}},
  author = {Laurie Chevalier and Annick Vachon and Mélanie Plourde},
  journal = {Journal of Nutrition},
  year = {2026},
  month = oct,
  doi = {10.1093/jn/nxaa458},
  url = {https://hal.science/hal-05790399v1},
  note = {CC BY-NC},
}
RIS
TY  - JOUR
TI  - Pharmacokinetics of Supplemental Omega-3 Fatty Acids Esterified in Monoglycerides, Ethyl Esters, or Triglycerides in Adults in a Randomized Crossover Trial
AU  - Laurie Chevalier
AU  - Annick Vachon
AU  - Mélanie Plourde
PY  - 2026
DA  - 2026/10/09
JO  - Journal of Nutrition
DO  - 10.1093/jn/nxaa458
UR  - https://hal.science/hal-05790399v1
AB  - BACKGROUND: Omega-3 (n-3) fatty acid (FA) supplements increase blood concentrations of EPA and DHA. Most of the supplements on the market are esterified in triglycerides (TGs) or ethyl esters (EEs), which limits their absorption and may cause gastrointestinal side effects. OBJECTIVE: The objective of this study was to compare the 24-h AUC of the plasma concentrations of EPA, DHA, and EPA+DHA when provided esterified in monoglycerides (MAGs), EEs, or TGs, (primary outcomes) and evaluate their side effects over 24 h (secondary outcome). METHODS: This was a randomized, triple-blind, crossover, controlled clinical trial. Eleven women and 11 men between 18 and 50 y of age ingested, in random order, a single oral dose of ∼1.2 g of EPA and DHA esterified in MAGs, EEs, and TGs with low-fat meals provided during the 24-h follow-up. Eleven blood samples over 24 h were collected from each participant, and the plasma n-3 FAs were quantified. Friedman's paired ANOVA statistical rank test was used for the pharmacokinetic parameters and a chi-square statistical test was used for the side effects. RESULTS: The 24-h AUC of plasma EPA was ∼2 times and ∼1 time higher after the MAG compared with the EE and TG forms of n-3 FAs, respectively (P ≤ 0.0027). Effects of the EE and TG treatments did not differ. The 3 supplements had similar eructation, dysgeusia, abdominal discomfort, nausea, and bloating side effects. CONCLUSIONS: The plasma n-3 FA concentration in adults is greater after acute supplementation with n-3 FAs esterified in MAGs rather than in EEs or TGs, suggesting that with a lower dose of MAG n-3 FAs, the plasma n-3 FA concentrations attained are similar to those after higher doses of n-3 FAs esterified in EEs or TGs. This trial is registered at www.clinicaltrials.gov as NCT03897660.
SN  - 0022-3166
SN  - 0022-3166
ER  -